About Caprotec
Caprotec is a company based in Berlin (Germany) founded in 2007 was acquired by Charles River Laboratories in July 2017. Caprotec has raised $15.33 million across 4 funding rounds from investors including Evotec, Charles River Laboratories and KfW. Caprotec operates in a competitive market with competitors including Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
- Headquarter Berlin, Germany
- SectorsHealthcare
- Website caprotec.com
- Social LinkedIn
- Acquired by Charles River Laboratories (Jul 2017)
- Total Equity Funding$15.33M (USD)
in 4 rounds
- Latest Funding Round$1.43M (USD), Series B
May 2011
- InvestorsEvotec
& 6 more
- Acquired byCharles River Laboratories
(Jul 2017)
Funding Insights of Caprotec
Caprotec has successfully raised a total of $15.33M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $1.43 million completed in May 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.33M
- Total Rounds 4
- Last Round Series B — $1.43M
- First Round $6.6M
(Nov 2007)
- Investors Count 6
All 4 funding rounds of Caprotec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2011 | $1.43M | Series B | – | LBBW Venture Capital | |
| May 2010 | $5.1M | Series B | – | – | |
| Jan 2008 | $2.2M | Series A | – | Creathor Venture, IBB Beteiligungsgesellschaft | |
| Nov 2007 | $6.6M | Series A | – | – | – |
7 investors in total: 6 institutional and 1 angel.
Investors in Caprotec
Caprotec has secured backing from 7 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Evotec, Charles River Laboratories and KfW.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage VC firm investing in smart & deep-tech, fin-tech and life science & health-tech sectors | – | lbbwvc.de | Stuttgart, Germany | |
- | – | creathor.com | - | |
Venture capital is provided to innovative startups in Berlin. | 1997 | ibb-bet.de | Berlin, Germany | |
Consumer and SME loans are provided across Germany. | 1948 | kfw.de | Frankfurt Am Main, Germany | |
Drug discovery and development services are provided to biopharma sector. | 1993 | evotec.com | Hamburg, Germany | |
Provider of drug discovery and preclinical development services | 1947 | criver.com | Wilmington, United States | |
HS Heinrich-Maria Schulte | - | – | unknown_0e2c777504d54af5b | - |
Investor details for Caprotec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Caprotec
4 dated milestones of Caprotec across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Caprotec is founded.
- Funding First funding round of $6.6M.
- Funding Latest funding round, Series B, of $1.4M.
- Exit Acquired by Charles River Laboratories.
Competitors of Caprotec
Caprotec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. | |
| biognosys.com | 2008 | Schlieren, Switzerland | $9.13M | – | Proteomics services are delivered via discovery and targeted platforms. | |
| elektrofi.com | 2016 | Boston, United States | $152.25M | 71 | Digital platform transforming the delivery of biologic medicines | |
| proteinsimple.com | 2004 | San Jose, United States | $114.29M | 157 | Provider tools to help researchers with protein analysis | |
| arzeda.com | 2008 | Seattle, United States | $94.96M | 66 | Synthetic enzymes are designed using computational technology for industrial applications. | |
| aalphabio.com | 2017 | Seattle, United States | $45.24M | 48 | Developer of cell-based tool for the measurements of protein interactions | |
| glyphic.bio | 2021 | San Francisco, United States | $39.2M | 26 | Next-generation protein sequencing platform is developed for proteome analysis. | |
| dynamic-biosensors.com | 2011 | Planegg, Germany | $5.83M | 51 | Label-free solutions for molecular interactions and biophysical analysis are provided. |
Detailed competitors of Caprotec
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Caprotec
Websites that share an audience with Caprotec (caprotec.com).
Websites whose visitors overlap most with Caprotec. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| selectscience.net | 100% | 117.5K | #363,624 | View details | |
genengnews.com | genengnews.com | 100% | – | #281,744 | – |
proteomicworld.org | proteomicworld.org | 88% | – | – | – |
| proteomics.com.au | 88% | 6K | #3,704,964 | View details | |
pfind.ict.ac.cn | pfind.ict.ac.cn | 88% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Caprotec
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Caprotec
Complete news archive for Caprotec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Caprotec
10 companies that operate in the same segment as Caprotec (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Caprotec
Caprotec was founded in 2007.
Caprotec is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
Caprotec is a funded company, having raised a total of $15.33M across 4 funding rounds to date. The company's 1st funding round was a Series A of $6.6M, raised on Nov 2007.
Caprotec was founded in 2007 in Berlin, Germany, within the biopharma sector focused on proteomics. A technology called Capture Compound Mass Spectrometry (CCMS) has been created to simplify protein mixtures through targeted reduction. Multifunctional small molecule probes are employed to target, capture, and isolate proteins by functionality. Operations involve collaborative research services for pharmaceutical and agrochemical firms.
Caprotec's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
Caprotec has 7 investors. Key investors include Evotec, Charles River Laboratories, KfW, LBBW Venture Capital, and Creathor Venture.
Yes. Caprotec was acquired by Charles River Laboratories in July 2017.